CD274 and nasopharyngeal carcinoma: Interestingly, treatment of HL with anti-PDL1 blocking antibodies is indeed proving valuable in the treatment of HL (188), whereas early trials in the context of NPC are giving mixed results with positive responses not always correlating with the PDL1 or HLA I status of tumor cells (189, 190).